

Page 1

ANDA 65-007

September 16, 1999

Ranbaxy Pharmaceuticals Inc.  
Attention: Shirley Ternyik  
U.S. Agent for: Ranbaxy Laboratories Limited  
600 College Road East  
Princeton, NJ 08540

Dear Madam:

This is in reference to your abbreviated new drug application dated January 27, 1998, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act, for Cephalexin Capsules USP, 250 mg (base) and 500 mg (base). We note that this product is subject to the exception provisions of Section 125(d)(2) of Title I of the Food and Drug Administration Modernization Act of 1997.

Reference is also made to your amendments dated May 20, and November 13, 1998; and March 19, May 28, June 15, July 16, and August 30, 1999.

We have completed the review of this abbreviated application and have concluded that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly, the application is approved. The Division of Bioequivalence has determined your Cephalexin Capsules USP, 250 mg (base) and 500 mg (base), to be bioequivalent and, therefore, therapeutically equivalent to the listed drug (Keflex<sup>7</sup> Capsules, 250 mg (base) and 500 mg (base), respectively, of Eli Lilly and Co.). Your dissolution testing should be incorporated into the stability and quality control program using the same method proposed in your application.

Under 21 CFR 314.70, certain changes in the conditions described in this abbreviated application require an approved supplemental application before the change may be made.

Post-marketing reporting requirements for this abbreviated application are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the

Page 2

marketing status of this drug.

We request that you submit, in duplicate, any proposed advertising or promotional copy that you intend to use in your initial advertising or promotional campaigns. Please submit all proposed materials in draft or mock-up form, not final print. Submit both copies together with a copy of the final printed labeling to the Division of Drug Marketing, Advertising, and Communications (HFD-40). Please do not use Form FD-2253 (Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use) for this initial submission.

We call your attention to 21 CFR 314.81(b)(3) which requires that materials for any subsequent advertising or promotional campaign be submitted to our Division of Drug Marketing, Advertising, and Communications (HFD-40) with a completed Form FD-2253 at the time of their initial use.

Sincerely yours,

Douglas L. Sporn  
Director  
Office of Generic Drugs  
Center for Drug Evaluation and Research